In a challenging market environment, scPharmaceuticals Inc. (NASDAQ:SCPH) stock has recorded a new 52-week low, dipping to $3.24. The biopharmaceutical company, which focuses on developing products for subcutaneous delivery, has faced significant headwinds over the past year, reflected in a substantial 1-year change with a decline of -33.07%. Investors have shown concern as the stock hit this low point, marking a notable downturn from its previous performance and raising questions about the company's future prospects amidst a volatile healthcare sector.
In other recent news, scPharmaceuticals reported a 24% increase in net revenue for the third quarter of 2024, totaling $10 million. This growth was largely due to the expansion of the sales force and a broader indication for FUROSCIX, now including Class IV heart failure patients. However, the company posted a net loss of $35.1 million for the quarter. Despite this, scPharmaceuticals' cash reserves increased to $91.5 million, following a significant financing round completed in August 2024.
The company is also looking forward to the potential FDA approval of FUROSCIX for treating edema in chronic kidney disease patients, with a Prescription Drug User Fee Act (PDUFA) date set for March 2025. Additionally, the company is optimistic about increased sales during the upcoming holiday season and expects significant adoption of an autoinjector, projecting over 90% of FUROSCIX prescriptions to use this method.
On the downside, the company experienced a higher net loss compared to the same quarter in the previous year, primarily due to one-time charges. The Gross-to-Net (GTN) discount for FUROSCIX exceeded anticipated ranges, causing revenue loss. Lastly, high co-pays led to prescription abandonment among patients, affecting the fill rate. Despite these challenges, scPharmaceuticals remains focused on its strategic initiatives, which are expected to drive growth in the coming year.
InvestingPro Insights
scPharmaceuticals Inc. (SCPH) has recently hit a new 52-week low, and InvestingPro data provides additional context to this development. The company's stock has experienced a sharp decline, with a 1-week price total return of -20.1% and a 1-month return of -21.13%, aligning with the article's mention of recent challenges. Despite these setbacks, SCPH shows some positive financial indicators. The company's revenue growth is impressive, with a 303.87% increase over the last twelve months as of Q3 2024, and a quarterly growth of 164.12% in Q3 2024.
InvestingPro Tips highlight that SCPH holds more cash than debt on its balance sheet, which could provide some financial stability during this turbulent period. Additionally, analysts anticipate sales growth in the current year, potentially offering a glimmer of hope for investors. However, it's crucial to note that the company is not profitable over the last twelve months, with an operating income margin of -210.35%.
For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips that could provide valuable insights into SCPH's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.